A Dose Escalation Study to Evaluate Safety, Tolerability Dosimetry, Pharmacokinetics and Preliminary Efficacy of 131I-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients
Phase of Trial: Phase I
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Tenatumomab I-131 (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors sigma-tau SpA
- 11 Jan 2018 Status changed from suspended to discontinued as update of drug into the tumour lesion was negligible
- 04 Nov 2016 Planned End Date changed from 1 Jun 2017 to 1 Feb 2018.
- 04 Nov 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.